Loading...

Fady Malik, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address505 Parnassus Avenue
San Francisco CA 94117
Phone415-353-3817
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Clinical Fellowship School of Medicine
    University of California, San Francisco Residency School of Medicine
    University of California, San FranciscoM.D.1994 Medicine
    University of California, San FranciscoPh.D.1993 Graduate Division (Neuroscience)

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail. 2020 Apr; 8(4):329-340. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. PMID: 32035892.
      View in: PubMed   Mentions:    Fields:    
    2. Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator tirasemtiv. Int J Mol Sci. 2019 Oct 10; 20(20). Lee EJ, Kolb J, Hwee DT, Malik FI, Granzier HL. PMID: 31658633.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    3. Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction. J Physiol. 2019 09; 597(17):4615-4625. Cheng AJ, Hwee DT, Kim LH, Durham N, Yang HT, Hinken AC, Kennedy AR, Terjung RL, Jasper JR, Malik FI, Westerblad H. PMID: 31246276.
      View in: PubMed   Mentions:    Fields:    
    4. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 0(0):1-11. Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. PMID: 31081694.
      View in: PubMed   Mentions: 1     Fields:    
    5. Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator. ACS Med Chem Lett. 2018 Apr 12; 9(4):354-358. Collibee SE, Bergnes G, Muci A, Browne WF, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ, Morgan BP. PMID: 29670700.
      View in: PubMed   Mentions:
    6. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):259-266. Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. PMID: 29402141.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    7. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018 01 30; 71(4):443-453. O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. PMID: 29389362.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018 01 01; 75(1):58-64. Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM. PMID: 29181534.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    9. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018 05; 57(5):729-734. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. PMID: 29150952.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    10. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun. 2017 08 04; 8(1):190. Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik FI, Houdusse A. PMID: 28775348.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    11. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovasc Drugs Ther. 2017 Aug; 31(4):445-458. Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. PMID: 28735360.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    12. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 06; 19(6):718-727. Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. PMID: 28345190.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. The Ca2+ sensitizer CK-2066260 increases myofibrillar Ca2+ sensitivity and submaximal force selectively in fast skeletal muscle. J Physiol. 2017 03 01; 595(5):1657-1670. Hwee DT, Cheng AJ, Hartman JJ, Hinken AC, Lee K, Durham N, Russell AJ, Malik FI, Westerblad H, Jasper JR. PMID: 27869319.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    14. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 12 10; 388(10062):2895-2903. Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N. PMID: 27914656.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    15. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):E7448-E7455. Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik FI, Houdusse AM. PMID: 27815532.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    16. Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health Qual Life Outcomes. 2016 Sep 15; 14(1):131. Wiklund I, Anatchkova M, Oko-Osi H, von Maltzahn R, Chau D, Malik FI, Patrick DL, Spertus J, Teerlink JR. PMID: 27629389.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. JACC Heart Fail. 2016 10; 4(10):791-804. Psotka MA, von Maltzahn R, Anatchkova M, Agodoa I, Chau D, Malik FI, Patrick DL, Spertus JA, Wiklund I, Teerlink JR. PMID: 27395351.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    18. Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016 07 01; 311(1):L20-8. Manders E, Bonta PI, Kloek JJ, Symersky P, Bogaard HJ, Hooijman PE, Jasper JR, Malik FI, Stienen GJ, Vonk-Noordegraaf A, de Man FS, Ottenheijm CA. PMID: 27190061.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    19. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016 Mar 29; 67(12):1444-1455. Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM. PMID: 27012405.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    20. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther. 2016 Mar; 54(3):217-27. Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, Monsalvo ML, Malik F. PMID: 26709596.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    21. Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity". Circ Heart Fail. 2015 Nov; 8(6):1141. Teerlink JR, Malik FI, Kass DA. PMID: 26578671.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    22. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015 Nov; 55(11):1236-47. Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT. PMID: 25951506.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    23. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics. 2015 Apr; 12(2):455-60. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI. PMID: 25742919.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    24. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015 Apr; 353(1):159-68. Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik FI, Jasper JR. PMID: 25678535.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    25. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2014 Dec; 50(6):925-31. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI. PMID: 24634285.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    26. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan; 3(1):22-9. Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. PMID: 25453536.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    27. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vasc Med. 2014 Aug; 19(4):297-306. Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR. PMID: 24872402.
      View in: PubMed   Mentions: 1     Fields:    
    28. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014; 9(5):e96921. Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR. PMID: 24805850.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    29. Novel drug mechanisms in development for heart failure. Pflugers Arch. 2014 Jun; 466(6):1219-25. Khodjaev SD, Teerlink JR, Malik FI. PMID: 24793049.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    30. Diaphragm fiber strength is reduced in critically ill patients and restored by a troponin activator. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):863-5. Hooijman PE, Beishuizen A, de Waard MC, de Man FS, Vermeijden JW, Steenvoorde P, Bouwman RA, Lommen W, van Hees HW, Heunks LM, Dickhoff C, van der Peet DL, Girbes AR, Jasper JR, Malik FI, Stienen GJ, Hartemink KJ, Paul MA, Ottenheijm CA. PMID: 24684359.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    31. Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle Nerve. 2013 Aug; 48(2):279-85. Miciak JJ, Warsing LC, Tibbs ME, Jasper JR, Jampel SB, Malik FI, Tankersley C, Wagner KR. PMID: 23512724.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    32. Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. Brain. 2013 Jun; 136(Pt 6):1718-31. Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik FI, Meng H, Stienen GJ, Beggs AH, Labeit S, Poggesi C, Lawlor MW, Granzier H. PMID: 23715096.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    33. Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. J Med Genet. 2013 Jun; 50(6):383-92. de Winter JM, Buck D, Hidalgo C, Jasper JR, Malik FI, Clarke NF, Stienen GJ, Lawlor MW, Beggs AH, Ottenheijm CA, Granzier H. PMID: 23572184.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    34. Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiency. PLoS One. 2013; 8(2):e55861. Lee EJ, De Winter JM, Buck D, Jasper JR, Malik FI, Labeit S, Ottenheijm CA, Granzier H. PMID: 23437068.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    35. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Sep; 13(5):430-8. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA. PMID: 22591195.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    36. Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension. PLoS One. 2012; 7(5):e36302. Ho D, Chen L, Zhao X, Durham N, Pannirselvam M, Vatner DE, Morgans DJ, Malik FI, Vatner SF, Shen YT. PMID: 22563487.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    37. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19; 18(3):452-5. Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne WF, Chen MM, Clarke D, Collibee SE, Garard M, Hansen R, Jia Z, Lu PP, Rodriguez H, Saikali KG, Schaletzky J, Vijayakumar V, Albertus DL, Claflin DR, Morgans DJ, Morgan BP, Malik FI. PMID: 22344294.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    38. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20; 378(9792):676-83. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. PMID: 21856481.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    39. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011 Aug 20; 378(9792):667-75. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. PMID: 21856480.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    40. Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension. J Pharmacol Exp Ther. 2011 Oct; 339(1):307-12. Zhao X, Ho D, Abarzúa P, Dhar SK, Wang X, Jia Z, Pannirselvam M, Morgans DJ, Malik FI, Vatner SF. PMID: 21784887.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    41. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011 Oct; 51(4):454-61. Malik FI, Morgan BP. PMID: 21616079.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    42. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18; 331(6023):1439-43. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. PMID: 21415352.
      View in: PubMed   Mentions: 134     Fields:    Translation:AnimalsCells
    43. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010 Dec 09; 1(9):472-7. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI, Morgans DJ. PMID: 24900233.
      View in: PubMed   Mentions:
    44. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010 Jul; 3(4):522-7. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. PMID: 20498236.
      View in: PubMed   Mentions: 39     Fields:    Translation:Animals
    Fady's Networks
    Concepts (213)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (3)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑